Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06112418 · ClinicalTrials.gov registry record · NA
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
A NA study of Diabetes Mellitus, Type 2 and Metabolic Syndrome, sponsored by Cleerly.
- Recruiting
- Registry status
- NA
- Development phase
- 7,500
- Enrollment target
- 20
- Study locations
NCT06112418 is a NA study of Diabetes Mellitus, Type 2 and Metabolic Syndrome that is actively recruiting participants, run by Cleerly. The registered enrollment target is 7,500 participants, above the 4,464-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (68% higher). The trial reports 20 study locations across 2 states.
The verdict
NCT06112418, a NA study of Diabetes Mellitus, Type 2 and Metabolic Syndrome, is actively recruiting participants, sponsored by Cleerly.
- RECRUITING
- Registry status
- NA
- Development phase
- 7,500 participants
- Enrollment target
- 20
- Study locations
Study Summary
TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.
Conditions Studied
Interventions
- DEVICE The Cleerly CAD Staging System
Study Locations (20)
California
- Cardiovascular Research Foundation of Southern California - Beverly Hills
- Amicis Research: Beverly Hills - Beverly Hills
- Valiance Clinical Research - Canoga Park - Canoga Park
- Cardiovascular Institute of San Diego - Chula Vista
- Amicis Research: Granada Hills - Granada Hills
- Valiance Clinical Research: Huntington Park - Huntington Park
- HALO Diagnostics - Indian Wells
- Scripps Health - La Jolla
- Chemidox Clinical Trials - Lancaster
- Long Beach Research Institute - Long Beach
- Ace Research Institute - Monterey Park - Monterey Park
- Amicis Research: Newhall - Newhall
- Ace Research Institute: Northridge - Northridge
- Amicis Research: Northridge - Northridge
- Ace Research Institute: Northridge #2 - Northridge
- Northridge Clinical Trials - Northridge
Arizona
- Chandler Clinical Trials - Chandler
- Scottsdale Clinical Trials - Scottsdale
- Sun City Research - Sun City
- Noble Clinical Research - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,500 participants |
| Start Date | 2024-03-06 |
| Est. Completion | 2029-03-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06112418
The ClinicalTrials.gov registry entry for NCT06112418 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 7,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 4,464-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (68% higher). The listed sponsor is Cleerly, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which The Cleerly CAD Staging System is the first listed.
NCT06112418 reports 20 study locations spanning 2 distinct geographic areas - top geographies include California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06112418 about?
NCT06112418 is a clinical study titled "A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events". TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (...
What is the current status of trial NCT06112418?
This trial is currently recruiting. It is a NA study. The enrollment target is 7,500 participants. The study started on 2024-03-06. Estimated completion is 2029-03-05.
What conditions does trial NCT06112418 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Metabolic Syndrome, PreDiabetes.
What interventions are being tested in trial NCT06112418?
The interventions under investigation include: The Cleerly CAD Staging System (DEVICE).
Who is sponsoring clinical trial NCT06112418?
This trial is sponsored by Cleerly, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06112418 being conducted?
This trial has 20 study locations across Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
RECRUITING · NA
-
Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic Population
RECRUITING · NA
-
Phenotyping Genetic Risk for Type 2 Diabetes
RECRUITING · NA
-
Diabetes Learning in Virtual Environments Just in Time for Community Reentry
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.